[China-Hong Kong Biotechnology]Tengsheng Biopharma (2137.HK) Announces Positive Clinical Data at IDWeek 2022 to Support Continued Development of Current Novel HIV Treatment Candidates
Tengsheng Boyao Biotechnology Co., Ltd. (hereinfollowing referred to as “Tengsheng Boyao” or the “Company”, stock code: 2137.HK), a multinational enterprise dedicated to developing innovative treatments for patients’ unmet needs and major public health diseases , today announced updated data from two Phase 1 studies in healthy U.S. volunteers evaluating the long-acting BRII-732 and BRII-778, two investigational drug candidates designed to treat human immunodeficiency virus (HIV) Infect. Results from both studies demonstrate that once-weekly dosing of BRII-732 and BRII-778 is safe and well-tolerated, a potential first-in-class oral once-weekly HIV combination therapy in development Provided important data support. The results of both studies were presented in a poster session at IDWeek 2022.
One of the posters, titled “Safety, Tolerability, and Pharmacokinetic Characteristics of Islatravir’s Medoxomil Carbonate Prodrug BRII-732 in Healthy Adult Subjects”, highlights the use of oral BRII-732 in a single escalating dose (SAD) up to 200 mg and multiple ascending doses (MAD) up to 25 mg, demonstrated acceptable safety and tolerability, and an excellent linear pharmacokinetic (PK) profile to achieve therapeutic targets. These data reinforce the therapeutic potential of BRII-732 as a combination antiretroviral regimen that includes once-weekly dosing.
“Our HIV research program aims to help improve standard of care for the more than 38 million people living with HIV around the world, many of whom want to better Manage this lifelong infection while enabling access to new treatment options that are more convenient to administer. These findings suggest that BRII-732 and BRII-778 hold promise as a safe and well-tolerated new patient treatment option that can help alleviate Patients’ daily medication burden, and even improve the social stigma that many people living with HIV currently face. We look forward to advancing the clinical development of two compounds, BRII-732 and BRII-778, into the next phase of research in an effort to provide patients with Provides the first oral long-acting combination therapy.”
Another poster presented at IDWeek titled “Safety, tolerability and pharmacokinetic profile of the modified-release oral formulation of Rilpivirine BRII-778 in healthy adult subjects” demonstrated BRII Single ascending dose (SAD) and multiple ascending dose (MAD) administration of -778 formulations are generally safe and well tolerated, with a linear pharmacokinetic (PK) profile consistent with slower oral absorption The ongoing clinical evaluation and development of BRII-778 as a potential once-weekly HIV treatment regimen provides key insights.
In addition, 16 abstracts published at IDWeek 2022 by Tengsheng Biopharmaceutical’s 3 strategic development partners showcased the infectious disease projects jointly developed with Tengsheng Biopharmaceuticals. This collective presentation on IDWeek further strengthens Tengsheng Biopharma’s scientific progress in developing a combination of anti-infective drugs to address a range of infectious diseases that impose significant public health burdens on people around the world. Among them, Tengsheng Biopharma has jointly promoted multidrug-resistant (MDR) and extensively drug-resistant (XDR) gram-negative bacterial infection treatment candidates with Qpex Biopharma in Greater China, and jointly promoted non-tuberculous mycobacteria treatment candidates with AN2 Therapeutics Licensing rights for drugs.
David Margolis, Ph.D., Head of Infectious Diseases Therapeutics at Tengsheng Biopharmaceuticals, said: “This set of strong clinical data from the Tengsheng Biopharmaceuticals HIV program and our collaborative projects in the field of multidrug-resistant (MDR) and extensively drug-resistant (XDR) antibiotics not only highlights The company’s expertise and leadership in infectious diseases is a testament to our ongoing commitment to developing unique treatment options for patients and providers in areas of great medical need and rapidly growing medical needs. Working to bridge the gap between scientific breakthroughs and patient needs, and working to develop innovative treatment candidates for some of the world’s most common diseases, including HIV. Current oral treatment options for HIV are limited to lifelong daily dosing, and many HIV Infected people believe that this method of administration is problematic and has seriously affected daily life.”
